Search

Your search keyword '"Rebuzzi, S.E."' showing total 29 results
Start Over Author "Rebuzzi, S.E."
29 results on '"Rebuzzi, S.E."'

1. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review

Author

Prelaj, A., Miskovic, V., Zanitti, M., Trovo, F., Genova, C., Viscardi, G., Rebuzzi, S.E., Mazzeo, L., Provenzano, L., Kosta, S., Favali, M., Spagnoletti, A., Castelo-Branco, L., Dolezal, J., Pearson, A.T., Lo Russo, G., Proto, C., Ganzinelli, M., Giani, C., Ambrosini, E., Turajlic, S., Au, L., Koopman, M., Delaloge, S., Kather, J.N., de Braud, F., Garassino, M.C., Pentheroudakis, G., Spencer, C., and Pedrocchi, A.L.G.

Published
2024
Full Text
View/download PDF

2. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

Author

Rebuzzi, S.E., Signori, A., Buti, S., Banna, G.L., Murianni, V., Damassi, A., Maruzzo, M., Giannarelli, D., Tortora, G., Galli, L., Rizzo, M., De Giorgi, U., Antonuzzo, L., Bracarda, S., Cartenì, G., Atzori, F., Tamberi, S., Procopio, G., Fratino, L., Lo Re, G., Santoni, M., Baldessari, C., Astone, A., Calabrò, F., Brunelli, M., Porta, C., Rescigno, P., Basso, U., and Fornarini, G.

Published
2022
Full Text
View/download PDF

3. Neutrophil-to-eosinophil ratio (NER) predicts the efficacy of avelumab in patients with advanced Urothelial Carcinoma (aUC) enrolled in the MALVA study (Meet-URO 25)

Author

Gambale, E., primary, MARUZZO, M., additional, MESSINA, C., additional, DE GENNARO AQUINO, I., additional, VASCOTTO, I.A., additional, ROSSI, V., additional, BIMBATTI, D., additional, CAVASIN, N., additional, MESSINA, M., additional, MENNITTO, A., additional, REBUZZI, S.E., additional, MERCINELLI, C., additional, FANELLI, M., additional, SORARù, M., additional, SCOLARI, F., additional, MELA, M.M., additional, GALLI, L., additional, DONI, L., additional, PILLOZZI, S., additional, and ANTONUZZO, L., additional

Published
2023
Full Text
View/download PDF

4. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

Author

Fornarini, G., Rebuzzi, S.E., Banna, G.L., Calabrò, F., Scandurra, G., De Giorgi, U., Masini, C., Baldessari, C., Naglieri, E., Caserta, C., Manacorda, S., Maruzzo, M., Milella, M., Buttigliero, C., Tambaro, R., Ermacora, P., Morelli, F., Nolè, F., Astolfi, C., and Sternberg, C.N.

Published
2021
Full Text
View/download PDF

5. 1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study

Author

Rebuzzi, S.E., primary, Rescigno, P., additional, Signori, A., additional, Brunelli, M., additional, Galuppini, F., additional, Vellone, V.G., additional, Gaggero, G., additional, Maruzzo, M., additional, Milella, M., additional, Vignani, F., additional, Cavo, A., additional, Basso, U., additional, Catalano, F., additional, Murianni, V., additional, Cremante, M., additional, Damassi, A., additional, Llaja Obispo, M.A., additional, Banna, G.L., additional, Buti, S., additional, and Fornarini, G., additional

Published
2022
Full Text
View/download PDF

7. 695P Drug-drug interactions between pazopanib and proton pump inhibitors may significantly affect clinical outcome of patients affected by metastatic renal cell carcinoma

Author

Del Re, M., primary, Brighi, N., additional, Rizzo, M., additional, Paolieri, F., additional, Rebuzzi, S.E., additional, Beninato, T., additional, Crucitta, S., additional, Mercinelli, C., additional, Gri, N., additional, Puglisi, S., additional, Verzoni, E., additional, Bleve, S., additional, Cucchiara, F., additional, Procopio, G., additional, Fornarini, G., additional, Galli, L., additional, Porta, C.G., additional, De Giorgi, U., additional, and Danesi, R., additional

Published
2021
Full Text
View/download PDF

8. 696P Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)

Author

Rebuzzi, S.E., primary, Signori, A., additional, Maruzzo, M., additional, Tortora, G., additional, Galli, L., additional, Rizzo, M., additional, De Giorgi, U., additional, Antonuzzo, L., additional, Bracarda, S., additional, Cartenì, G., additional, Atzori, F., additional, Tamberi, S., additional, Procopio, G., additional, Fratino, L., additional, Santoni, M., additional, Baldessari, C., additional, Astone, A., additional, Calabro', F., additional, Buti, S., additional, and Fornarini, G., additional

Published
2021
Full Text
View/download PDF

9. P216 - Neutrophil-to-eosinophil ratio (NER) predicts the efficacy of avelumab in patients with advanced Urothelial Carcinoma (aUC) enrolled in the MALVA study (Meet-URO 25)

Author

Gambale, E., MARUZZO, M., MESSINA, C., DE GENNARO AQUINO, I., VASCOTTO, I.A., ROSSI, V., BIMBATTI, D., CAVASIN, N., MESSINA, M., MENNITTO, A., REBUZZI, S.E., MERCINELLI, C., FANELLI, M., SORARù, M., SCOLARI, F., MELA, M.M., GALLI, L., DONI, L., PILLOZZI, S., and ANTONUZZO, L.

Published
2023
Full Text
View/download PDF

10. 1895P Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)

Author

Rebuzzi, S.E., Signori, A., Buti, S., Maruzzo, M., De Giorgi, U.F.F., Zucali, P.A., Procopio, G., Fratino, L., Pipitone, S., Mollica, V., Soraru, M., Chiellino, S., Lipari, H., Galli, L., Masini, C., Naglieri, E., Milella, M., Ricotta, R., Banna, G.L., and Fornarini, G.

Published
2023
Full Text
View/download PDF

11. 192TiP Radiological morphological (MF) and radiomic features (RF) of brain metastases in oncogene-addicted advanced non-small cell lung cancer (NSCLC) patients: Diagnostic implications and prognostic role (BRAIN Lung study)

Author

Rebuzzi, S.E., primary, Barletta, L., additional, Rosso, E., additional, Maddalo, M., additional, Signori, A., additional, Catalano, F., additional, Grassi, M., additional, Tagliamento, M., additional, Rossi, G., additional, Dal Bello, M.G., additional, Mazzaschi, G., additional, Barabino, E., additional, Fedeli, A., additional, Doni, M., additional, Tiseo, M., additional, and Genova, C., additional

Published
2021
Full Text
View/download PDF

12. 802TiP Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study

Author

Brunelli, M., primary, Buti, S., additional, Rebuzzi, S.E., additional, Milella, M., additional, Vellone, V., additional, Bersanelli, M., additional, Maruzzo, M., additional, Basso, U., additional, Signori, A., additional, Martelli, V., additional, Catalano, F., additional, Damassi, A., additional, Murianni, V., additional, Merler, S., additional, Casartelli, C., additional, and Fornarini, G., additional

Published
2020
Full Text
View/download PDF

13. 767P Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammation index (SII) as prognostic factors in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis of the Italian population of the SAUL study

Author

Rebuzzi, S.E., primary, Sternberg, C.N., additional, Banna, G.L., additional, Ermacora, P., additional, Morelli, F., additional, Nolè, F., additional, Marandino, L., additional, Panni, S., additional, Massari, F., additional, Hamzaj, A., additional, Milesi, L., additional, Santini, D., additional, De Tursi, M., additional, Scartozzi, M., additional, Astolfi, C., additional, and Fornarini, G., additional

Published
2020
Full Text
View/download PDF

14. 768P Prognostic score combining systemic inflammation index (SII) and PD-L1 +/- LDH in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis in the Italian population of the SAUL study

Author

Rebuzzi, S.E., primary, Sternberg, C.N., additional, Fornarini, G., additional, Calabro', F., additional, Baldessari, C., additional, Scandurra, G., additional, De Giorgi, U., additional, Masini, C., additional, Naglieri, E., additional, Caserta, C., additional, Galli, L., additional, Maruzzo, M., additional, Zampiva, I., additional, Buttigliero, C., additional, Astolfi, C., additional, and Banna, G.L., additional

Published
2020
Full Text
View/download PDF

15. 399O Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial

Author

Rosati, G., primary, Galli, F., additional, Lonardi, S., additional, Dotti, K.F., additional, Ronzoni, M., additional, Zampino, M.G., additional, Banzi, M., additional, Pusceddu, V., additional, Pasini, F., additional, Bozzarelli, S., additional, Pella, N., additional, Codecà, C., additional, Montesarchio, V., additional, Mambrini, A., additional, De Stefano, A., additional, Ciuffreda, L., additional, Rebuzzi, S.E., additional, Bilancia, D., additional, and Labianca, R., additional

Published
2020
Full Text
View/download PDF

16. Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients

Author

Prelaj, A., primary, Rebuzzi, S.E., additional, Pizzutilo, P., additional, Bilancia, M., additional, Montrone, M., additional, Pesola, F., additional, Longo, V., additional, Del Bene, G., additional, Lapadula, V., additional, Cassano, F., additional, Petrillo, P., additional, Bafunno, D., additional, Varesano, N., additional, Lamorgese, V., additional, Mastranrdea, A., additional, Ricci, D., additional, Catino, A., additional, and Galetta, D., additional

Published
2019
Full Text
View/download PDF

17. Time-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients

Author

Prelaj, A., primary, Rebuzzi, S.E., additional, Pizzutilo, P., additional, Bilancia, M., additional, Montrone, M., additional, Pesola, F., additional, Longo, V., additional, Del Bene, G., additional, Lapadula, V., additional, Cassano, F., additional, Petrillo, P., additional, Bafunno, D., additional, Varesano, N., additional, Lamorgese, V., additional, Mastranrdea, A., additional, Ricci, D., additional, Catino, A., additional, and Galetta, D., additional

Published
2019
Full Text
View/download PDF

18. Predictive score using clinical and blood biomarkers in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy

Author

Prelaj, A., primary, Rebuzzi, S.E., additional, Pizzutilo, P., additional, Montrone, M., additional, Pesola, F., additional, Longo, V., additional, Lapadula, V., additional, Cassano, F., additional, Petrillo, P., additional, Bafunno, D., additional, Varesano, N., additional, Lamorgese, V., additional, Mastrandrea, A., additional, Ricci, D., additional, Catino, A., additional, and Domenico, G., additional

Published
2018
Full Text
View/download PDF

21. Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in large cell neuroendocrine carcinoma

Author

Prelaj, A., primary, Rebuzzi, S.E., additional, Del Bene, G., additional, Giròn Berrìos, J.R., additional, Emiliani, A., additional, De Filippis, L., additional, Pecorari, S., additional, Prete, A.A., additional, Manna, G., additional, Ferrara, C., additional, Rossini, D., additional, and Longo, F., additional

Published
2017
Full Text
View/download PDF

27. Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib

Author

Sara Elena Rebuzzi, Luigi Cerbone, Alessio Signori, Matteo Santoni, Veronica Murianni, Ugo De Giorgi, Giuseppe Procopio, Camillo Porta, Michele Milella, Umberto Basso, Francesco Massari, Marco Maruzzo, Roberto Iacovelli, Nicola Battelli, Luca Carmisciano, Giuseppe Luigi Banna, Sebastiano Buti, Giuseppe Fornarini, Rebuzzi S.E., Cerbone L., Signori A., Santoni M., Murianni V., De Giorgi U., Procopio G., Porta C., Milella M., Basso U., Massari F., Maruzzo M., Iacovelli R., Battelli N., Carmisciano L., Banna G.L., Buti S., and Fornarini G.

Subjects
renal cell carcinoma, Oncology, cabozantinib, target therapy, clinical factors, biomarkers, prognostic score, biomarker, clinical factor
Abstract

Background: The addition of neutrophil-to-lymphocyte ratio (NLR) and bone metastases to the International Metastatic RCC Database Consortium (IMDC) score (by the Meet-URO score) has been shown to better stratify pretreated metastatic renal cell carcinoma (mRCC) patients receiving nivolumab. This study aimed to validate the Meet-URO score in patients receiving cabozantinib to assess its predictivity and prognostic role. Methods: A multicenter retrospective analysis evaluated mRCC patients receiving ⩾second-line cabozantinib. NLR, IMDC score and bone metastases were assessed before the start of cabozantinib. The primary endpoint was overall survival (OS). Harrell’s c-index was calculated to compare the accuracy of the prediction of the two scores. Results: Overall, 174 mRCC patients received cabozantinib as second and third line (51.7% and 48.3%, respectively) with a median follow-up of 6.8 months. A shorter median overall survival (mOS) was observed for the IMDC poor-risk group, NLR ⩾3.2 and the presence of bone metastases, while the IMDC intermediate-risk group had a similar mOS to the favourable-risk one. Applying the Meet-URO score, three risk groups were identified: group 1 (55.2% of patients) with a score of 0–3, group 2 (38.5%) with a score of 4–8 and group 3 (6.3%) with a score of 9. Compared to group 1 (mOS: 39.4 months), a statistically significant worse mOS was observed in group 2 (11.2 months) and group 3 (3.2 months) patients, respectively. The Meet-URO c-index score was 0.640, showing a higher discriminative ability than the IMDC score ( c-index: 0.568). Conclusion: This analysis showed that the Meet-URO score provides a more accurate prognostic stratification than the IMDC score in mRCC patients treated with ⩾second-line cabozantinib besides nivolumab. Moreover, it is an easy-to-use tool with no additional costs for clinical practice (web-calculator is available at: https://proviso.shinyapps.io/Meet-URO15_score/ ). Future investigations will include the application of the Meet-URO score to the first-line immunotherapy-based combination therapies.

Published
2022

28. Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study

Author

Matteo Brunelli, Guido Martignoni, Giorgio Malpeli, Alessandro Volpe, Luca Cima, Maria Rosaria Raspollini, Mattia Barbareschi, Alessandro Tafuri, Giulia Masi, Luisa Barzon, Serena Ammendola, Manuela Villanova, Maria Angela Cerruto, Michele Milella, Sebastiano Buti, Melissa Bersanelli, Giuseppe Fornarini, Sara Elena Rebuzzi, Valerio Gaetano Vellone, Gabriele Gaggero, Giuseppe Procopio, Elena Verzoni, Sergio Bracarda, Martina Fanelli, Roberto Sabbatini, Rodolfo Passalacqua, Bruno Perrucci, Maria Olga Giganti, Maddalena Donini, Stefano Panni, Marcello Tucci, Veronica Prati, Cinzia Ortega, Anna Caliò, Albino Eccher, Filippo Alongi, Giovanni Pappagallo, Roberto Iacovelli, Alessandra Mosca, Paolo Umari, Ilaria Montagnani, Stefano Gobbo, Francesco Atzori, Enrico Munari, Marco Maruzzo, Umberto Basso, Francesco Pierconti, Carlo Patriarca, Piergiuseppe Colombo, Alberto Lapini, Giario Conti, Roberto Salvioni, Enrico Bollito, Andrea Cossarizza, Francesco Massari, Mimma Rizzo, Renato Franco, Federica Zito-Marino, Yoseba Aberasturi Plata, Francesca Galuppini, Marta Sbaraglia, Matteo Fassan, Angelo Paolo Dei Tos, Maurizio Colecchia, Holger Moch, Maurizio Scaltriti, Camillo Porta, Brett Delahunt, Gianluca Giannarini, Roberto Bortolus, Pasquale Rescigno, Giuseppe Luigi Banna, Alessio Signori, Miguel Angel Llaja Obispo, Roberto Perris, Alessandro Antonelli, Brunelli, Matteo, Martignoni, Guido, Malpeli, Giorgio, Volpe, Alessandro, Cima, Luca, Raspollini, Maria Rosaria, Barbareschi, Mattia, Tafuri, Alessandro, Masi, Giulia, Barzon, Luisa, Ammendola, Serena, Villanova, Manuela, Cerruto, Maria Angela, Milella, Michele, Buti, Sebastiano, Bersanelli, Melissa, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Vellone, Valerio Gaetano, Gaggero, Gabriele, Procopio, Giuseppe, Verzoni, Elena, Bracarda, Sergio, Fanelli, Martina, Sabbatini, Roberto, Passalacqua, Rodolfo, Perrucci, Bruno, Giganti, Maria Olga, Donini, Maddalena, Panni, Stefano, Tucci, Marcello, Prati, Veronica, Ortega, Cinzia, Caliò, Anna, Eccher, Albino, Alongi, Filippo, Pappagallo, Giovanni, Iacovelli, Roberto, Mosca, Alessandra, Umari, Paolo, Montagnani, Ilaria, Gobbo, Stefano, Atzori, Francesco, Munari, Enrico, Maruzzo, Marco, Basso, Umberto, Pierconti, Francesco, Patriarca, Carlo, Colombo, Piergiuseppe, Lapini, Alberto, Conti, Giario, Salvioni, Roberto, Bollito, Enrico, Cossarizza, Andrea, Massari, Francesco, Rizzo, Mimma, Franco, Renato, Zito-Marino, Federica, Aberasturi Plata, Yoseba, Galuppini, Francesca, Sbaraglia, Marta, Fassan, Matteo, Dei Tos, Angelo Paolo, Colecchia, Maurizio, Moch, Holger, Scaltriti, Maurizio, Porta, Camillo, Delahunt, Brett, Giannarini, Gianluca, Bortolus, Roberto, Rescigno, Pasquale, Banna, Giuseppe Luigi, Signori, Alessio, Obispo, Miguel Angel Llaja, Perris, Roberto, Antonelli, Alessandro, Brunelli M., Martignoni G., Malpeli G., Volpe A., Cima L., Raspollini M.R., Barbareschi M., Tafuri A., Masi G., Barzon L., Ammendola S., Villanova M., Cerruto M.A., Milella M., Buti S., Bersanelli M., Fornarini G., Rebuzzi S.E., Vellone V.G., Gaggero G., Procopio G., Verzoni E., Bracarda S., Fanelli M., Sabbatini R., Passalacqua R., Perrucci B., Giganti M.O., Donini M., Panni S., Tucci M., Prati V., Ortega C., Calio A., Eccher A., Alongi F., Pappagallo G., Iacovelli R., Mosca A., Umari P., Montagnani I., Gobbo S., Atzori F., Munari E., Maruzzo M., Basso U., Pierconti F., Patriarca C., Colombo P., Lapini A., Conti G., Salvioni R., Bollito E., Cossarizza A., Massari F., Rizzo M., Franco R., Zito-Marino F., Plata Y.A., Galuppini F., Sbaraglia M., Fassan M., Dei Tos A.P., Colecchia M., Moch H., Scaltriti M., Porta C., Delahunt B., Giannarini G., Bortolus R., Rescigno P., Banna G.L., Signori A., Obispo M.A.L., Perris R., and Antonelli A.

Subjects
angiogenesis, clear cell renal cell carcinoma, tumor sampling, intratumoral heterogeneity, immunity, immunohistochemistry, Medicine (miscellaneous), angiogenesi
Abstract

We aimed to overcome intratumoral heterogeneity in clear cell renal cell carcinoma (clearRCC). One hundred cases of clearRCC were sampled. First, usual standard sampling was applied (1 block/cm of tumor); second, the whole tumor was sampled, and 0.6 mm cores were taken from each block to construct a tissue microarray; third, the residual tissue, mapped by taking pieces 0.5 × 0.5 cm, reconstructed the entire tumor mass. Precisely, six randomly derived pieces of tissues were placed in each cassette, with the number of cassettes being based on the diameter of the tumor (called multisite 3D fusion). Angiogenic and immune markers were tested. Routine 5231 tissue blocks were obtained. Multisite 3D fusion sections showed pattern A, homogeneous high vascular density (10%), pattern B, homogeneous low vascular density (8%) and pattern C, heterogeneous angiogenic signatures (82%). PD-L1 expression was seen as diffuse (7%), low (33%) and absent (60%). Tumor-infiltrating CD8 scored high in 25% (pattern hot), low in 65% (pattern weak) and zero in 10% of cases (pattern desert). Grading was upgraded in 26% of cases (G3–G4), necrosis and sarcomatoid/rhabdoid characters were observed in, respectively, 11 and 7% of cases after 3D fusion (p = 0.03). CD8 and PD-L1 immune expressions were higher in the undifferentiated G4/rhabdoid/sarcomatoid clearRCC subtypes (p = 0.03). Again, 22% of cases were set to intermediate to high risk of clinical recurrence due to new morphological findings of all aggressive G4, sarcomatoid/rhabdoid features by using 3D fusion compared to standard methods (p = 0.04). In conclusion, we propose an easy-to-apply multisite 3D fusion sampling that negates bias due to tumor heterogeneity.

Published
2022

29. Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives

Author

Sara Elena Rebuzzi, Pasquale Rescigno, Fabio Catalano, Veronica Mollica, Ursula Maria Vogl, Laura Marandino, Francesco Massari, Ricardo Pereira Mestre, Elisa Zanardi, Alessio Signori, Sebastiano Buti, Matteo Bauckneht, Silke Gillessen, Giuseppe Luigi Banna, Giuseppe Fornarini, Rebuzzi S.E., Rescigno P., Catalano F., Mollica V., Vogl U.M., Marandino L., Massari F., Mestre R.P., Zanardi E., Signori A., Buti S., Bauckneht M., Gillessen S., Banna G.L., and Fornarini G.

Subjects
Castration-resistant, Castration-sensitive, Immune checkpoint inhibitor, Immunotherapy, Molecular oncology, Predictive biomarkers, Prognostic biomarkers, Prostate cancer, Tumor microenvironment, Cancer Research, Prognostic biomarker, Predictive biomarker, Oncology
Abstract

In the last 10 years, many new therapeutic options have been approved in advanced prostate cancer (PCa) patients, granting a more prolonged survival in patients with metastatic disease, which, nevertheless, remains incurable. The emphasis on immune checkpoint inhibitors (ICIs) has led to many trials in this setting, with disappointing results until now. Therefore, we discuss the immunobiology of PCa, presenting ongoing trials and the available clinical data, to understand if immunotherapy could represent a valid option in this disease, and which subset of patients may be more likely to benefit. Current evidence suggests that the tumor microenvironment needs a qualitative rather than quantitative evaluation, along with the genomic determinants of prostate tumor cells. The prognostic or predictive value of immunotherapy biomarkers, such as PD-L1, TMB, or dMMR/MSI-high, needs further evaluation in PCa. Monotherapy with immune checkpoint inhibitors (ICIs) has been modestly effective. In contrast, combined strategies with other standard treatments (hormonal agents, chemotherapy, PARP inhibitors, radium-223, and TKIs) have shown some results. Immunotherapy should be better investigated in biomarker-selected patients, particularly with specific pathway aberrations (e.g., AR-V7 variant, HRD, CDK12 inactivated tumors, MSI-high tumors). Lastly, we present new possible targets in PCa that could potentially modulate the tumor microenvironment and improve antitumor activity with ICIs.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results